Geron (GERN) names Harout Semerjian as CEO; 11M options granted

Q: Who is the new CEO of Geron (GERN) and when does the appointment take effect?

Harout Semerjian was appointed President and Chief Executive Officer, effective August 7, 2025 .

Q: What are the key financial terms of Harout Semerjian鈥檚 employment at Geron (GERN)?

The Employment Agreement provides a $800,000 annual base salary and an annual performance target bonus equal to 70% of base salary (prorated for 2025).

Q: What equity compensation did Geron (GERN) grant to the new CEO?

Geron will grant options to purchase 11,000,000 shares under the 2018 Inducement Award Plan; vesting: 7,000,000 (12.5% at 6 months then monthly over 42 months) and 4,000,000 (25% at 1 year then monthly over 36 months); full vest on Change in Control.

Q: What plan amendments were approved by Geron鈥檚 Compensation Committee on August 1, 2025?

The Compensation Committee approved an Amended and Restated Severance Plan adding a CEO payment equal to 150% of target bonus upon a qualifying Change of Control and amended the 2018 Inducement Award Plan to increase the share reserve by 11,000,000 shares for inducement grants.

[8-K] Geron Corp Reports Material Event

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Event: Geron Corporation (GERN) filed an 8-K reporting the appointment of Harout Semerjian as President, Chief Executive Officer and director, effective August 7, 2025.

CEO appointment: Mr. Semerjian replaces Dawn C. Bir and will fill a Class I board vacancy through the 2027 annual meeting.
Compensation: Annual base salary $800,000; annual performance target bonus 70% of base salary (prorated for 2025).
Equity inducement: Grant of stock options to purchase 11,000,000 shares under the 2018 Inducement Award Plan; exercise price = Nasdaq closing price on start/grant date.
Vesting: 7,000,000 options: 12.5% at six months then monthly over 42 months; 4,000,000 options: 25% at one year then monthly over 36 months; full vest upon Change in Control.
Severance: Covered Termination: prorated target bonus, lump-sum equal to 18 months base salary, COBRA for up to 18 months; vested options remain exercisable until earlier of two years post-termination or original expiration.
Plan amendments: Amended and Restated Severance Plan effective August 1, 2025 adds a CEO payment equal to 150% of target bonus upon a qualifying Change of Control; 2018 Inducement Award Plan amended to add 11,000,000 shares for inducement grants.
Exhibits: Employment Agreement (Exhibit 10.1), Amended Severance Plan (Exhibit 10.2), Amended 2018 Inducement Plan (Exhibit 10.3).

靷贝: Geron Corporation (GERN)鞚€ 8-K毳� 鞝滌稖頃橃棳 Harout Semerjian鞚� 2025雲� 8鞗� 7鞚茧秬搿� 靷灔, 斓滉碃瓴届榿鞛�(CEO) 氚� 鞚挫偓搿� 靹犾瀯頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟.

CEO 靹犾瀯: Semerjian 鞌姅 Dawn C. Bir毳� 雽€鞁犿晿氅� 2027雲� 鞐半 欤检＜齑濏殞旯岇 韥措灅鞀� I 鞚挫偓須� 瓿奠劃鞚� 毂勳泚雼堧嫟.
氤挫垬: 鞐瓣皠旮半掣旮� $800,000; 鞐瓣皠靹标臣氇╉憸氤措剤鞀る姅旮半掣旮夓潣 70% (2025雲勳潃鞚柬暊瓿勳偘).
欤检嫕鞚胳劶韹半笇: 2018 Inducement Award Plan鞐� 霐半澕 11,000,000欤茧ゼ毵れ垬頃� 靾� 鞛堧姅鞀ろ啞鞓奠厴攵€鞐�; 頄夓偓臧€瓴� = 鞁滌瀾/攵€鞐澕鞚� 雮橃姢雼� 膦呹皜.
氩犾姢韺�: 7,000,000 鞓奠厴: 6臧滌洈鞁� 12.5% 氩犾姢韺� 頉� 42臧滌洈臧� 毵れ洈氩犾姢韺�; 4,000,000 鞓奠厴: 1雲� 鞁� 25% 氩犾姢韺� 頉� 36臧滌洈臧� 毵れ洈氩犾姢韺�; Change in Control 氚滌儩鞁� 鞝勳暋氩犾姢韺�.
頃搓碃鞁� 氤挫儊: 鞝侅毄霅橂姅膦呺鞚� 瓴届毎: 氇╉憸氤措剤鞀れ潣牍勲 歆€旮�, 旮半掣旮� 18臧滌洈攵勳棎頃措嫻頃橂姅鞚检嫓旮�, COBRA 斓滊寑 18臧滌洈; 鞚措 氩犾姢韺呺悳鞓奠厴鞚€ 膦呺 頉� 2雲� 霕愲姅鞗愲灅毵岅赴鞚� 欷� 牍犽ジ鞁滌爯旯岇 頄夓偓臧€電�.
瓿勴殟靾橃爼: 2025雲� 8鞗� 1鞚茧秬搿� 氚滍毃霅� Amended and Restated Severance Plan鞚€ 鞛愱博鞛堧姅 Change of Control 氚滌儩鞁� CEO鞐愱矊氇╉憸氤措剤鞀れ潣 150%鞐� 頃措嫻頃橂姅歆€旮夓潉於旉皜頃橁碃, 2018 Inducement Award Plan鞚€ 鞚胳劶韹半笇攵€鞐毄鞙茧 11,000,000欤茧ゼ於旉皜頃橂弰搿� 臧滌爼霅橃棃鞀惦媹雼�.
歃濍箼靹滊: 瓿犾毄瓿勳暯靹�(Exhibit 10.1), 靾橃爼霅� Severance Plan(Exhibit 10.2), 靾橃爼霅� 2018 Inducement Plan(Exhibit 10.3).

Positive

Experienced CEO appointment: Harout Semerjian brings commercial and hematology experience from Novartis, Ipsen and GlycoMimetics.
Clear compensation terms: Base salary ($800,000), target bonus (70%) and detailed severance provisions are disclosed.
Retention and alignment: Large inducement option grant with multi-year vesting schedules and full vesting on Change in Control align long-term incentives.
Formal plan amendments: Inducement award plan and severance plan changes are documented and filed as exhibits.

Negative

Potential dilution: Grant of 11,000,000 stock options and corresponding 11,000,000 share increase to the inducement plan increase potential share count and dilution.
Generous severance/CIC protections: 18 months salary plus additional 150% of target bonus upon Change in Control for CEO could be costly to shareholders.
Materiality not quantified: Filing does not disclose current total shares outstanding or the exercise price (will equal closing price on start date), limiting immediate assessment of dilution magnitude.

Insights

TL;DR: New CEO hire with detailed employment, equity inducement and enhanced severance terms; governance implications on dilution and change-in-control protections.

The Board appointed Harout Semerjian effective August 7, 2025, with a documented employment agreement and indemnification agreement. The filing discloses a large inducement option grant (11,000,000 shares) and amendments to the severance and inducement plans. Material governance points: (i) the option grant is expressly a Nasdaq Rule 5635(c)(4) inducement award and the inducement plan reserve is increased accordingly; (ii) the Amended Severance Plan and the Employment Agreement provide enhanced change-in-control and severance protections (notably 18 months salary and additional 150% target bonus in a CIC for the CEO). These terms are significant for shareholders due to potential dilution and post-termination payouts, and should be monitored alongside outstanding share counts and potential future disclosures on option pricing and run-rate compensation.

TL;DR: Commercially experienced CEO recruited with market-level cash pay and front-loaded option inducements tied to service and CIC protections.

Mr. Semerjian鈥檚 background in commercial leadership (Novartis, Ipsen, GlycoMimetics) aligns with Geron鈥檚 stated rationale for his appointment. The employment package combines a $800,000 base, 70% target bonus and a sizable 11,000,000 option grant with staggered vesting and full CIC vesting鈥攖ypical for senior biotech CEO inducements but large in absolute share terms. Severance terms (18 months salary, prorated bonus, 18 months COBRA) and the amended plan鈥檚 150% bonus on CIC materially enhance downside protections for the CEO. From a compensation design perspective, the structure mixes retention through graded vesting and protection via CIC vesting; investors should weigh retention benefits against share reserve expansion and potential dilution.

CEO 靹犾瀯: Semerjian 鞌姅 Dawn C. Bir毳� 雽€鞁犿晿氅� 2027雲� 鞐半 欤检＜齑濏殞旯岇 韥措灅鞀� I 鞚挫偓須� 瓿奠劃鞚� 毂勳泚雼堧嫟.
氤挫垬: 鞐瓣皠旮半掣旮� $800,000; 鞐瓣皠靹标臣氇╉憸氤措剤鞀る姅旮半掣旮夓潣 70% (2025雲勳潃鞚柬暊瓿勳偘).
欤检嫕鞚胳劶韹半笇: 2018 Inducement Award Plan鞐� 霐半澕 11,000,000欤茧ゼ毵れ垬頃� 靾� 鞛堧姅鞀ろ啞鞓奠厴攵€鞐�; 頄夓偓臧€瓴� = 鞁滌瀾/攵€鞐澕鞚� 雮橃姢雼� 膦呹皜.
氩犾姢韺�: 7,000,000 鞓奠厴: 6臧滌洈鞁� 12.5% 氩犾姢韺� 頉� 42臧滌洈臧� 毵れ洈氩犾姢韺�; 4,000,000 鞓奠厴: 1雲� 鞁� 25% 氩犾姢韺� 頉� 36臧滌洈臧� 毵れ洈氩犾姢韺�; Change in Control 氚滌儩鞁� 鞝勳暋氩犾姢韺�.
頃搓碃鞁� 氤挫儊: 鞝侅毄霅橂姅膦呺鞚� 瓴届毎: 氇╉憸氤措剤鞀れ潣牍勲 歆€旮�, 旮半掣旮� 18臧滌洈攵勳棎頃措嫻頃橂姅鞚检嫓旮�, COBRA 斓滊寑 18臧滌洈; 鞚措 氩犾姢韺呺悳鞓奠厴鞚€ 膦呺 頉� 2雲� 霕愲姅鞗愲灅毵岅赴鞚� 欷� 牍犽ジ鞁滌爯旯岇 頄夓偓臧€電�.
瓿勴殟靾橃爼: 2025雲� 8鞗� 1鞚茧秬搿� 氚滍毃霅� Amended and Restated Severance Plan鞚€ 鞛愱博鞛堧姅 Change of Control 氚滌儩鞁� CEO鞐愱矊氇╉憸氤措剤鞀れ潣 150%鞐� 頃措嫻頃橂姅歆€旮夓潉於旉皜頃橁碃, 2018 Inducement Award Plan鞚€ 鞚胳劶韹半笇攵€鞐毄鞙茧 11,000,000欤茧ゼ於旉皜頃橂弰搿� 臧滌爼霅橃棃鞀惦媹雼�.
歃濍箼靹滊: 瓿犾毄瓿勳暯靹�(Exhibit 10.1), 靾橃爼霅� Severance Plan(Exhibit 10.2), 靾橃爼霅� 2018 Inducement Plan(Exhibit 10.3).

08/06/2025 - 04:16 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

___________

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 1, 2025

GERON CORPORATION

(Exact name of registrant as specified in its charter)


Delaware	000-20859	75-2287752
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

919 E. HILLSDALE BLVD., SUITE 250

FOSTER CITY, CALIFORNIA 94404

(Address of principal executive offices, including zip code)

(650) 473-7700

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value	GERN	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 1, 2025, the Board of Directors (the “Board”) of Geron Corporation (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating and Corporate Governance Committee”), appointed Harout Semerjian as President and Chief Executive Officer of the Company and as a director, effective August 7, 2025 (the “Effective Date”). On the Effective Date, Mr. Semerjian will be appointed to the Board to fill the existing vacancy as a Class I director for a term expiring at the Company’s 2027 annual meeting of stockholders. Mr. Semerjian replaces Dawn C. Bir, who ceased serving as Interim President and Chief Executive Officer of the Company immediately prior to Mr. Semerjian’s appointment. Ms. Bir will continue to serve as a member of the Board.

Mr. Semerjian, age 54, most recently served as President and Chief Executive Officer of GlycoMimetics, Inc., a late-stage clinical biotechnology company subsequently combined with Crescent Biopharma, Inc., from August 2021 until February 2025. He also previously served on the board of directors of GlycoMimetics. Since October 2023, Mr. Semerjian has also served as a member of the board of directors at the Biotechnology Innovation Organization. From June 2020 to July 2021, Mr. Semerjian served as an independent healthcare consultant at Emerge Bio Consulting, advising private equity firms on healthcare investment projects. Mr. Semerjian served as President and Chief Executive Officer of Immunomedics Inc., a biotechnology company specializing in antibody-drug conjugates for cancer treatment, from April 2020 to May 2020, prior to its acquisition by Gilead Sciences, Inc. From March 2018 to April 2020, Mr. Semerjian served as Executive Vice President, Chief Commercial Officer of Ipsen Pharma, a global, pharmaceutical company focusing on areas of high unmet medical need, leading and executing Ipsen’s global commercial strategy and functions across oncology, neurosciences and rare diseases. From February 2017 to February 2018, he served as President and Head of Ipsen’s Specialty Care International Region & Global Franchises. From 1994 to January 2017, Mr. Semerjian held several commercial, marketing and sales positions of increasing responsibility within Novartis Pharmaceuticals, a global pharmaceutical company, including serving as Senior Vice President and Global Launch Leader for KISQALI®, in regional vice president hematology and oncology roles in the U.S., MENA and the Nordics, and as global brand director for Gleevec®, as well as for Merck, a global pharmaceutical company, and Solvay, a multinational chemical and materials company. Mr. Semerjian holds an MBA from Cornell University and Queen's University in Canada, and a B.S. in Biology from Lebanese American University. The Board believes Mr. Semerjian’s deep commercial and hematology expertise, broad leadership experience, and global perspective qualify him to serve on the Board.

In connection with Mr. Semerjian’s appointment as the Company’s President and Chief Executive Officer, the Board, acting upon the recommendation of the Compensation Committee of the Board (the “Compensation Committee”), approved the Company’s entry into an employment agreement with Mr. Semerjian, effective as of the Effective Date (the “Employment Agreement”). The Employment Agreement provides for an annual base salary of $800,000 and an annual performance target bonus of 70% of his annual base salary, which will be prorated for 2025. In addition, the Company has agreed to grant Mr. Semerjian a stock option to purchase 11,000,000 shares of the Company’s common stock (the “Stock Options”) pursuant to the Company’s 2018 Inducement Award Plan (as defined below). The Stock Options will vest and become exercisable as follows: (i) 7,000,000 of the Stock Options will vest as to 12.5% of the shares underlying the grant on the six-month anniversary of the grant date, with the remaining shares vesting in equal monthly installments over the following 42 months; and (ii) 4,000,000 of the Stock Options will vest as to 25% of the shares underlying the grant on the first anniversary of the grant date, with the remaining shares vesting in equal monthly installments over the following 36 months, in each case subject to Mr. Semerjian’s continued service to the Company on the vesting dates. The Stock Options will be granted as a material inducement to Mr. Semerjian’s employment under the Company’s 2018 Inducement Award Plan and will have an exercise price equal to the closing price of the Company’s common stock on the Nasdaq Global Select Market on his start date, which will be the grant date. The Stock Options will fully vest upon the occurrence of a Change in Control (as defined in the Employment Agreement). Under the terms of the Employment Agreement, Mr. Semerjian is not eligible for an annual equity award until 2027.

The Employment Agreement also provides that Mr. Semerjian is entitled to severance benefits consistent with the Company’s other executive officers. In the event Mr. Semerjian’s employment is terminated due to a Covered Termination (as defined in the Employment Agreement), (i) he will be paid his target annual bonus for the fiscal year in which the termination occurs, prorated for length of service during the year, and a lump-sum severance payment equal to 18 months of his base salary then in effect as of such termination; (ii) he and his covered dependents will also be eligible to continued healthcare coverage as permitted by COBRA for a period of up to 18 months following a Covered Termination, at the Company’s expense; and (iii) the vested portion of any stock options granted to Mr. Semerjian by the Company shall remain outstanding and exercisable until the earlier of the second anniversary of the date of termination or the original

expiration date of such award. Mr. Semerjian is also eligible to participate in the Amended Severance Plan (as defined below).

The foregoing description of the Employment Agreement is a summary of its material terms, does not purport to be complete and is qualified in its entirety by reference to the full text of the Employment Agreement, which is attached hereto as Exhibit 10.1 and is incorporated herein by reference.

There is no arrangement or understanding between Mr. Semerjian and any other person pursuant to which Mr. Semerjian was appointed as President, Chief Executive Officer and a director of the Company, and there is no family relationship between Mr. Semerjian and any of the Company’s other directors or executive officers. In addition, Mr. Semerjian is not party to any transaction, or series of transactions, required to be disclosed pursuant to Item 404(a) of Regulation S-K.

In connection with his appointment, the Company and Mr. Semerjian will enter into the Company’s standard form of indemnification agreement. Pursuant to the terms of the indemnification agreement, the Company may be required, among other things, to indemnify Mr. Semerjian for certain expenses, including attorneys’ fees, judgments, fines and settlement amounts incurred by him in any action or proceeding arising out of his service as President, Chief Executive Officer and a director of the Company. The foregoing is only a brief description of the terms of the indemnification agreement with Mr. Semerjian, does not purport to be complete and is qualified in its entirety by reference to the form of indemnification agreement, previously filed as Exhibit 10.1 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2011, as filed on March 7, 2012.

Amended and Restated Severance Plan

Effective August 1, 2025, the Compensation Committee approved the Company’s Amended and Restated Severance Plan (as so amended and restated, the “Amended Severance Plan”), which Amended Severance Plan amends and restates, in its entirety, the amended and restated severance plan previously approved by the Board on December 23, 2021. The Amended Severance Plan applies to (i) eligible employees of the Company who were hired by the Company on or before December 31, 2021, and (ii) certain designated key employees of the Company, including the Company’s executive officers, in each case, who are not subject to a performance improvement plan. The only change to the existing severance plan is to add a payment to the Chief Executive Officer of 150% of his or her annual target bonus upon a Separation of Service (as defined in the Amended Severance Plan) in connection with a Change of Control (as defined in the Amended Severance Plan), as further described below.

Under the Amended Severance Plan, upon a Change of Control Triggering Event (and provided such Triggering Event constitutes a Separation from Service (as defined therein)), each of the Company’s executive officers, including Mr. Semerjian, is entitled to: (i) a severance payment equal to 15 months (18 months, with respect to Mr. Semerjian) of his or her base salary then in effect; (ii) payment of his or her target annual bonus, at the target bonus percentage in effect immediately prior to the termination, prorated for length of service during the year (plus an additional payment equal to 150% of his target annual bonus, with respect to Mr. Semerjian); and (iii) payment of COBRA premiums for up to 15 months (18 months, with respect to Mr. Semerjian). The Company’s executive officers will continue to receive the greater of the severance benefits set forth in their employment agreements or the severance benefits provided for in the Amended Severance Plan (without duplication).

The foregoing description of the Amended Severance Plan does not purport to be complete and is qualified in its entirety by the full text of the Amended Severance Plan, which is attached hereto as Exhibit 10.2 and is incorporated herein by reference.

Amendment to 2018 Inducement Award Plan

Effective August 1, 2025, the Compensation Committee approved an amendment to the Company’s 2018 Inducement Award Plan to increase the number of shares of the Company’s common stock issuable thereunder by 11,000,000 shares (as so amended and restated, the “Amended 2018 Inducement Plan”) to be used exclusively for grants of inducement awards to individuals who were not previously employees or directors of the Company, other than following a bona fide period of non-employment, as a material inducement within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules to each such individual’s entry into employment with the Company.

The foregoing description of the Amended 2018 Inducement Plan does not purport to be complete and is qualified in its entirety by the full text of the Amended 2018 Inducement Plan, which is attached hereto as Exhibit 10.3 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits.


Exhibit No.			Description
10.1			Employment Agreement by and between the Company and Harout Semerjian, effective August 7, 2025.
10.2			Geron Corporation Amended and Restated Severance Plan, as amended.
10.3			Geron Corporation 2018 Inducement Award Plan, as amended.
104			Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


		GERON CORPORATION

Date: August 6, 2025	By:	/s/ Scott A. Samuels
	Name:	Scott A. Samuels
	Title:	Executive Vice President,
		Chief Legal Officer and Secretary

Source:

FAQ

Who is the new CEO of Geron (GERN) and when does the appointment take effect?

Harout Semerjian was appointed President and Chief Executive Officer, effective August 7, 2025.

What are the key financial terms of Harout Semerjian鈥檚 employment at Geron (GERN)?

The Employment Agreement provides a $800,000 annual base salary and an annual performance target bonus equal to 70% of base salary (prorated for 2025).

What equity compensation did Geron (GERN) grant to the new CEO?

Geron will grant options to purchase 11,000,000 shares under the 2018 Inducement Award Plan; vesting: 7,000,000 (12.5% at 6 months then monthly over 42 months) and 4,000,000 (25% at 1 year then monthly over 36 months); full vest on Change in Control.

What severance protections does the CEO receive under Geron鈥檚 agreements?

For a Covered Termination the CEO is entitled to a prorated target bonus, a lump-sum severance equal to 18 months of base salary, COBRA healthcare coverage for up to 18 months, and extended exercisability of vested options for up to two years (subject to original expiration).

What plan amendments were approved by Geron鈥檚 Compensation Committee on August 1, 2025?

The Compensation Committee approved an Amended and Restated Severance Plan adding a CEO payment equal to 150% of target bonus upon a qualifying Change of Control and amended the 2018 Inducement Award Plan to increase the share reserve by 11,000,000 shares for inducement grants.

AG真人官方

[8-K] Geron Corp Reports Material Event

Insights

FAQ

Who is the new CEO of Geron (GERN) and when does the appointment take effect?

What are the key financial terms of Harout Semerjian鈥檚 employment at Geron (GERN)?

What equity compensation did Geron (GERN) grant to the new CEO?

What severance protections does the CEO receive under Geron鈥檚 agreements?

What plan amendments were approved by Geron鈥檚 Compensation Committee on August 1, 2025?

NASDAQ:GERN

GERN Rankings

GERN Latest News

GERN Latest SEC Filings

GERN Stock Data

AG真人官方

Trending News

[8-K] Geron Corp Reports Material Event

Insights

Corporate Governance Expert positive

Biotech C-Suite Compensation Analyst positive

FAQ

Who is the new CEO of Geron (GERN) and when does the appointment take effect?

What are the key financial terms of Harout Semerjian鈥檚 employment at Geron (GERN)?

What equity compensation did Geron (GERN) grant to the new CEO?

What severance protections does the CEO receive under Geron鈥檚 agreements?

What plan amendments were approved by Geron鈥檚 Compensation Committee on August 1, 2025?

NASDAQ:GERN

GERN Rankings

GERN Latest News

GERN Latest SEC Filings

GERN Stock Data